DOCSLIB.ORG

Randomized Trial of Intermediate-Dose Cytarabine In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Randomized Trial of Intermediate-Dose Cytarabine In Published OnlineFirst February 6, 2020; DOI: 10.1158/1078-0432.CCR-19-3433 CLINICAL CANCER RESEARCH | CLINICAL TRIALS: TARGETED THERAPY Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia Hui Wei1,2,3, Ying Wang2,3, Robert Peter Gale4, Dong Lin3, Chunlin Zhou3, Bingcheng Liu3, Shaowei Qiu3, Runxia Gu3, Yan Li3, Xingli Zhao3, Shuning Wei3, Benfa Gong3, Kaiqi Liu3, Xiaoyuan Gong3, Yuntao Liu3, Guangji Zhang3, Zhen Song2, Yang Wang5, Wei Li5, Yingchang Mi1,2,3, and Jianxiang Wang1,2,3 ABSTRACT ◥ Purpose: Cytarabine, 100–200 mg/mEþ2/day, is commonly Results: 591 subjects were randomized to intermediate- (N ¼ used in induction therapy of acute myelogenous leukemia (AML). 295) or conventional-dose (N ¼ 296) cytarabine group. Three-year Whether a higher dose of cytarabine would be more effective is DFSs were 67% [95% confidence interval (CI), 61–73] in the unknown. Also, there is controversy whether high-dose cytarabine intermediate-dose cohort compared with 54% (95% CI, 48–61) in is better than an intermediate-dose combined with other drugs for the conventional-dose cohort [Hazard Ratio (HR), 0.67; 95%CI, post-remission therapy. In this open-label, randomized controlled, 0.51–0.89; P ¼ 0.005). Three-year survivals were 68% (95%CI, parallel group study, roles of intermediate-dose cytarabine were 63–74) and 59% (95%CI, 53–65; HR, 0.720; 95%CI, 0.56–0.94; investigated. P ¼ 0.014). Two courses of intermediate-dose cytarabine with Patients and Methods: Subjects with AML age 15–55 years daunorubicin or mitoxantrone resulted in similar DFS and survival were randomized to receive daunorubicin, omacetaxine mepesuc- as three courses of high-dose cytarabine when used for post- cinate, and conventional- or intermediate-dose cytarabine. Subjects remission therapy. achieving complete remission were randomized to receive 3 courses Conclusions: Induction therapy with intermediate-dose cytar- of high-dose cytarabine or 2 courses of intermediate-dose cytar- abine with daunorubicin and omacetaxine mepesuccinate increases abine with daunorubicin in the 1st and mitoxantrone in the 2nd DFS and survival in persons with AML ages 15–55 years compared course. The primary endpoint was disease-free survival (DFS). with conventional-dose cytarabine. Introduction included subjects of diverse ages that might explain some discordances as might center effects. Cytarabine is a common component of induction therapy of acute The standard remission induction regimen in China is cytarabine myelogenous leukemia (AML). Cytarabine, 100–200 mg/mEþ2/day and daunorubicin combined with omacetaxine mepesuccinate (homo- for 5–10 days, typically 7 days, is typically combined with daunoru- harringtonine). Because of the bone marrow suppression associated bicin, 60–90 mg/mEþ2/day for 3 days (1–3). Higher doses of cytar- with homoharringtonine the dose of daunorubicin is typically reduced abine, namely intermediate-dose (1–2 g/mEþ2/day) and high-dose to 40 mg/mEþ2/day for 3 days rather than the 60 mg/mEþ2/day used (2–3 g/mEþ2/day) were tested in several clinical trials with contra- when homoharringtonine is not given (reviewed in Supplementary dictory results (4–10). Some studies reported no survival benefit(4–6) Table S2; refs. 11–18). In the pilot study for this trial, we used whereas others reported better relapse-free survival (reviewed in intermediate-dose cytarabine combined with daunorubicin and Supplementary Table S1; refs, 4–8, 10). These multicenter studies homoharringtonine. Three-year disease-free survival (DFS) was 63% [95% confidence interval (CI), 51–76] and three-year survival, 59% (95%CI, 46–71; ref. 13). 1State Key Laboratory of Experimental Hematology, Tianjin, China. 2National High-dose cytarabine is commonly used as post-remission (con- Clinical Research Center for Blood Disease, Tianjin, China. 3Leukemia Center, solidation) therapy (19–23). Intermediate-dose cytarabine alone or Institute of Hematology and Blood Diseases Hospital, Chinese Academy of combined with other drugs are also widely used for post-remission 4 Medical Sciences, Tianjin, China. Division of Experimental Medicine, Depart- therapy (12, 13, 21, 24, 25). In our study, we also compared efficacy ment of Medicine, Hematology Research Center, Imperial College London, of high-dose cytarabine versus intermediate-dose cytarabine com- London, United Kingdom. 5State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union bined with daunorubicin and mitoxantrone for post-remission Medical College and Chinese Academy of Medical Sciences, Tianjin, China. therapy. Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/). Patients and Methods H. Wei and Y. Wang contributed equally to the article. Study design and participants Corresponding Authors: Jianxiang Wang, Institute of Hematology and Blood This study was an open-label, randomized controlled, parallel group Diseases Hospital, Chinese Academy of Medical Sciences, Nanjing Road 288, single-center trial conducted at the Blood Disease Hospital, Chinese Tianjin 300020, China. Phone/Fax: 8622-2390-9120; E-mail: [email protected]; and Yingchang Mi, [email protected] Academy of Medical Science from September 1, 2010 to January 13, 2016 registered at www.chictr.org.cn (identifier: ChiCTR-TRC- Clin Cancer Res 2020;XX:XX–XX 10001202). The study was approved by the Hospital Ethics Committee doi: 10.1158/1078-0432.CCR-19-3433 and conducted in accordance with the Declaration of Helsinki. Sub- Ó2020 American Association for Cancer Research. jects gave written informed consent. AACRJournals.org | OF1 Downloaded from clincancerres.aacrjournals.org on September 24, 2021. © 2020 American Association for Cancer Research. Published OnlineFirst February 6, 2020; DOI: 10.1158/1078-0432.CCR-19-3433 Wei et al. subjects were not blinded to therapy-assignment but investigators Translational Relevance assessing outcomes and statisticians were. Cytarabine is commonly used in acute myelogenous leukemia (AML). Whether an induction regimen with intermediate-dose Treatment cytarabine would be more effective than one with conventional Eligible subjects were randomly assigned to conventional- dose is unknown. Also, there is controversy whether high-dose (100 mg/mEþ2/day days 1–7 as a 12-hour intravenous infusion) or cytarabine is better than an intermediate-dose combined with other intermediate-dose cytarabine (100 mg/mEþ2/day days 1–4asa drugs for post-remission therapy. In this open-label, randomized 12-hour intravenous infusion and 1 g/mEþ2 every 12 hours as a controlled, parallel group trial, we show that intermediate-dose 3-hour intravenous infusion on days 5–7). Subjects also received dau- cytarabine induction combined daunorubicin and omacetaxine norubicin (40 mg/mEþ2/day on days 1–3) and omacetaxine mepe- mepesuccinate produced a higher rate of complete remissions, succinate (2 mg/mEþ2/day on days 1–7). A CONSORT flow diagram better event- and disease-free survival (EFS and DFS) and survival and treatment scheme are displayed in Figs. 1 and 2. Criteria for compared with conventional-dose cytarabine with no increase in response and relapse followed the Report of the National Cancer early deaths in young adults with new-diagnosed de novo AML. In Institute-Sponsored Workshop (27). For subjects randomized to contrast, there was no difference in cumulative incidence of relapse conventional-dose cytarabine, a 2nd induction course, identical to the (CIR), DFS or survival between intermediate- and high-dose 1st, could be given if a partial remission was achieved after 1st induction cytarabine given for post-remission consolidation. cycle and when blood cell counts recovered. From March 1, 2013 subjects randomized to receive conventional-dose cytarabine with bone marrow blasts ≥10% on day 14 could receive a 2nd induction course of cytarabine (100 mg/mEþ2/day on days 1–5 as a 12-hour Newly diagnosed persons with de novo AML excluding acute intravenous infusion) and daunorubicin (45 mg/mEþ2/day days 1–3). promyelocytic leukemia age 15 ≤ 55 years were eligible. Main Subjects randomized to receive intermediate-dose cytarabine did not inclusion criteria were: (i) AML according to WHO classification receive a 2nd induction course because of hematopoietic toxicity. (2008; ref. 26); (ii) ECOG performance score ≤2; (iii) cardiac Subjects achieving a complete remission were randomized to receive ejection-fraction determined by echocardiography ≥50%; (iv) three courses of high-dose cytarabine (3 g/mEþ2 days 1–3 every serum total bilirubin concentration <1.5 Â upper limit normal 12 hours as a 3-hour intravenous infusion) or two courses of (ULN), aspartate aminotransferase and alanine aminotransferase intermediate-dose cytarabine (1.5 g/mEþ2 at the same schedule) with concentrations <2.5 Â ULN, serum creatinine concentration <2.0 Â daunorubicin (40 mg/mEþ2/day on days 1–3) in the first and mitox- ULN and cardiac enzymes <2.0 ULN. antrone (6 mg/mEþ2/day on days 1–3) in the second courses. The There were two 1:1 randomization that were computer-generated second randomization was not stratified for induction regimen. with allocation concealment in an unreadable computer system that Subjects could receive 4 cycles of intrathecal methotrexate, cytarabine, investigators could access only after a subject was enrolled. Random- and dexamethasone to prevent CNS leukemia if they agreed. ization sequence
Load more

Recommended publications
  • A Systematic Review of the Effectiveness of Docetaxel and Mitoxantrone for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
    British Journal of Cancer (2006) 95, 457 – 462 & 2006 Cancer Research UK All rights reserved 0007 – 0920/06 $30.00 www.bjcancer.com A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer *,1 1 1 1 2 3 4 5 R Collins , R Trowman , G Norman , K Light , A Birtle , E Fenwick , S Palmer and R Riemsma 1 2 Centre for Reviews and Dissemination, University of York, Heslington, York YO10 5DD, UK; Rosemere Cancer Centre, Royal Preston Hospital, Sharoe 3 Green Lane North, Fulwood, Preston PR2 9HT, UK; Public Health & Health Policy, Division of Community Based Sciences, University of Glasgow, 4 5 1 Lilybank Gardens, Glasgow G12 8RZ, UK; Centre for Health Economics, University of York, Heslington, York YO10 5DD, UK; Kleijnen Systematic Reviews Ltd, Westminster Business Centre, 10 Great North Way, Nether Poppleton, York YO26 6RB, UK Clinical Studies A systematic review was performed to evaluate the clinical effectiveness of docetaxel in combination with prednisolone (docetaxel is licensed in the UK for use in combination with prednisone or prednisolone for the treatment of patients with metastatic hormone- refractory prostate cancer. Prednisone is not used in the UK, but it is reasonable to use docetaxel plus prednisone data in this review of docetaxel plus prednisolone) for the treatment of metastatic hormone-refractory prostate cancer. A scoping search identified a trial of docetaxel plus prednisone vs mitoxantrone plus prednisone, but did not identify any trials comparing docetaxel plus prednisolone/prednisone with any other treatments. Therefore, we considered additional indirect evidence that would enable a comparison of docetaxel plus prednisolone/prednisone with other chemotherapy regimens and active supportive care.
    [Show full text]
  • Gy Total Body Irradiation Followed by Allogeneic Hematopoietic St
    Bone Marrow Transplantation (2009) 44, 785–792 & 2009 Macmillan Publishers Limited All rights reserved 0268-3369/09 $32.00 www.nature.com/bmt ORIGINAL ARTICLE Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia F Zohren, A Czibere, I Bruns, R Fenk, T Schroeder, T Gra¨f, R Haas and G Kobbe Department of Haematology, Oncology and Clinical Immunology, Heinrich Heine-University, Du¨sseldorf, Germany In this prospective study, we examined the toxicity and Introduction efficacy of an intensified conditioning regimen for treatment of patients with relapsed or high-risk acute The use of intensified conventional induction chemothera- lymphoblastic leukemia who undergo allogeneic hemato- pies in the treatment of newly diagnosed ALL in adult poietic stem cell transplantation. Fifteen patients received patients has led to initial CR rates of up to 90%. But, as fludarabine 30 mg/m2, cytarabine 2000 mg/m2, amsacrine some patients are even refractory to first-line therapy, the 100 mg/m2 on days -10, -9, -8 and -7, anti-thymocyte majority of the responding patients unfortunately suffer globulin (ATG-Fresenius) 20 mg/kg body weight on days from relapse. Therefore, the probability of long-term -6, -5 and -4 and fractionated total body irradiation disease-free survival is o30%.1–5 Risk stratification based 2 Â 2 Gy on days -3, -2 and -1 (FLAMSA-ATG-TBI) on prognostic factors allows identification of high-risk before allogeneic hematopoietic stem cell transplantation. ALL patients with poor prognosis.6–12 Myeloablative At the time of hematopoietic stem cell transplantation, 10 conditioning therapy followed by allogeneic hematopoietic patients were in complete remission (8 CR1; 2 CR2), 3 stem cell transplantation (HSCT) is currently the treatment with primary refractory and 2 suffered from refractory of choice for these high-risk patients.13–15 A combination of relapse.
    [Show full text]
  • Idamycin PFS® Idarubicin Hydrochloride Injection
    Idamycin PFS® idarubicin hydrochloride injection Rx only FOR INTRAVENOUS USE ONLY WARNINGS 1. IDAMYCIN PFS Injection should be given slowly into a freely flowing intravenous infusion. It must never be given intramuscularly or subcutaneously. Severe local tissue necrosis can occur if there is extravasation during administration. 2. As is the case with other anthracyclines the use of IDAMYCIN PFS can cause myocardial toxicity leading to congestive heart failure. Cardiac toxicity is more common in patients who have received prior anthracyclines or who have pre- existing cardiac disease. 3. As is usual with antileukemic agents, severe myelosuppression occurs when IDAMYCIN PFS is used at effective therapeutic doses. 4. It is recommended that IDAMYCIN PFS be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection. 5. Dosage should be reduced in patients with impaired hepatic or renal function. (See DOSAGE AND ADMINISTRATION.) DESCRIPTION IDAMYCIN PFS Injection contains idarubicin hydrochloride and is a sterile, semi- synthetic, preservative-free solution (PFS) antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride is 5, 12-Naphthacenedione, 9-acetyl-7-[(3- amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11- trihydroxyhydrochloride, (7S-cis). The structural formula is as follows: C26 H27 NO9 .HCL M.W. 533.96 1 Reference ID: 3668307 IDAMYCIN PFS is a sterile, red-orange, isotonic parenteral preservative-free solution, available in 5 mL (5 mg), 10 mL (10 mg) and 20 mL (20 mg) single-use-only vials.
    [Show full text]
  • SYN-40585 SYNRIBO Digital PI, Pil and IFU 5/2021 V3.Indd
    SYN-40585 CONTRAINDICATIONS HIGHLIGHTS OF PRESCRIBING INFORMATION None. These highlights do not include all the information needed to use SYNRIBO safely and WARNINGS AND PRECAUTIONS effectively. See full prescribing information for SYNRIBO. • Myelosuppression: Severe and fatal thrombocytopenia, neutropenia and anemia. Monitor SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use hematologic parameters frequently (2.3, 5.1). Initial U.S. Approval: 2012 • Bleeding: Severe thrombocytopenia and increased risk of hemorrhage. Fatal cerebral hemorrhage and severe, non-fatal gastrointestinal hemorrhage (5.1, 5.2). INDICATIONS AND USAGE Hyperglycemia: Glucose intolerance and hyperglycemia including hyperosmolar non-ketotic SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated • hyperglycemia (5.3). phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the tyrosine kinase inhibitors (TKI) (1). • potential risk to a fetus and to use an effective method of contraception (5.4, 8.1, 8.3). DOSAGE AND ADMINISTRATION ADVERSE REACTIONS Induction Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for • Most common adverse reactions (frequency ≥ 20%): thrombocytopenia, anemia, neutropenia, 14 consecutive days of a 28-day cycle (2.1). diarrhea, nausea, fatigue, asthenia, injection site reaction, pyrexia, infection, and lymphopenia Maintenance Dose: 1.25 mg/m2 administered by subcutaneous injection twice daily for • (6.1). 7 consecutive days of a 28-day cycle (2.2). • Dose modifications are needed for toxicity (2.3). To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
    [Show full text]
  • NOVANTRONE (Mitoxantrone for Injection Concentrate) in Patients with Hepatic Insufficiency Is Not Established (See CLINICAL PHARMACOLOGY)
    NOVANTRONE® mitoXANTRONE for injection concentrate WARNING NOVANTRONE® (mitoxantrone for injection concentrate) should be administered under the supervision of a physician experienced in the use of cytotoxic chemotherapy agents. NOVANTRONE® should be given slowly into a freely flowing intravenous infusion. It must never be given subcutaneously, intramuscularly, or intra-arterially. Severe local tissue damage may occur if there is extravasation during administration. (See ADVERSE REACTIONS, General, Cutaneous and DOSAGE AND ADMINISTRATION, Preparation and Administration Precautions). NOT FOR INTRATHECAL USE. Severe injury with permanent sequelae can result from intrathecal administration. (See WARNINGS, General) Except for the treatment of acute nonlymphocytic leukemia, NOVANTRONE® therapy generally should not be given to patients with baseline neutrophil counts of less than 1,500 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving NOVANTRONE®. Cardiotoxicity: Congestive heart failure (CHF), potentially fatal, may occur either during therapy with NOVANTRONE® or months to years after termination of therapy. Cardiotoxicity risk increases with cumulative NOVANTRONE dose and may occur whether or not cardiac risk factors are present. Presence or history of cardiovascular disease, radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or use of other cardiotoxic drugs may increase this risk. In cancer patients, the risk of symptomatic CHF was estimated to be 2.6% for patients receiving up to a cumulative dose of 140 mg/m2. To mitigate the cardiotoxicity risk with NOVANTRONE, prescribers should consider the following: NOVANTRONE mitoXANTRONE for injection 1 All Patients: - All patients should be assessed for cardiac signs and symptoms by history, physical examination, and ECG prior to start of NOVANTRONE® therapy.
    [Show full text]
  • CK0403, a 9‑Aminoacridine, Is a Potent Anti‑Cancer Agent in Human Breast Cancer Cells
    MOLECULAR MEDICINE REPORTS 13: 933-938, 2016 CK0403, a 9‑aminoacridine, is a potent anti‑cancer agent in human breast cancer cells YUAN-WAN SUN1, KUEN-YUAN CHEN2, CHUL-HOON KWON3 and KUN-MING CHEN1 1Department of Biochemistry and Molecular Biology, College of Medicine, Pennsylvania State University, Hershey, PA 17033, USA; 2Department of Surgery, National Taiwan University Hospital, Taipei 8862, Taiwan, R.O.C.; 3Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, New York, NY 11439, USA Received November 11, 2014; Accepted October 22, 2015 DOI: 10.3892/mmr.2015.4604 Abstract. 3-({4-[4-(Acridin-9-ylamino)phenylthio]phenyl} reduced growth inhibitory activity under hypoxic conditions, (3-hydroxypropyl)amino)propan-1-ol (CK0403) is a which can induce autophagy. Collectively, the present results sulfur-containing 9-anilinoacridine analogue of amsacrine and supported that CK0403 is highly potent and more effective than was found to be more potent than its analogue 2-({4-[4-(acridin- CK0402 against estrogen receptor-negative and 9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino) HER2-overexpressing breast cancer cell lines, suggesting its ethan-1-ol (CK0402) and amsacrine in the inhibition of the future application for chemotherapy in breast cancer. topoisomerase II-catalyzed decatenation reaction. A previous study by our group reported that CK0402 was effective against Introduction numerous breast cancer cell lines, and the combination of CK0402 with herceptin enhanced its activity in HER2(+) Breast cancer is the most common type of cancer diagnosed SKBR-3 cells. In order to identify novel chemotherapeutic agents in American women and is the second most common cause with enhanced potency, the present study explored the potential of cancer-associated mortality.
    [Show full text]
  • Burkitt Lymphoma
    NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Burkitt Lymphoma (Part 1 of 3) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Induction Therapy—Low Risk Combination Regimens1,a Note: All recommendations are Category 2A unless otherwise indicated. REGIMEN DOSING CODOX-M
    [Show full text]
  • Idarubicin.Pdf
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrIDARUBICIN idarubicin hydrochloride injection Preservative Free Solution, 1 mg/mL, intravenous injection Antineoplastic Agent Pfizer Canada ULC Date of Initial Authorization: 17,300 Trans-Canada Highway July 30, 2013 Kirkland, Quebec, H9J 2M5 Date of Revision: September 14, 2021 Submission Control Number: 255782 ©Pfizer Canada ULC, 2021 IDARUBICIN (idarubicin hydrochloride injection) Page 1 of 31 RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, Cardiovascular JA/2021 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ..........................................................................................2 TABLE OF CONTENTS ............................................................................................................2 1 INDICATIONS.............................................................................................................4 1.1 Pediatrics .................................................................................................................4 1.2 Geriatrics..................................................................................................................4 2 CONTRAINDICATIONS................................................................................................4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ...........................................................5 4 DOSAGE AND ADMINISTRATION................................................................................5
    [Show full text]
  • Summary Attachment for Eudract
    Avenue E. Mounier 83/11 1200 Brussels Belgium Tel: +32 2 774 1611 Email: [email protected] www.eortc.org Summary Attachment for EudraCT Name of Individual study Table Referring to Part of the Dossier (For National Authority Use Sponsor/Company: Only) EORTC Name of the Volume: finished product Name of Active Page Ingredients: Clofarabine Cytarabine Idarubicin Title of the Study Clofarabine in combination with a standard remissioninduction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS) : a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial) Investigators & Study Centers Number of Country City patients Belgium 4 101.Hopital Jules Bordet (BE) Brussels 1 109.A.Z. St Jan (BE) Brugge 3 Italy 28 3931.Tor Vergata Roma (IT) Roma 12 733.La Sapienza Ematologia (IT) Roma 16 Netherlands 43 304.RU Nijmegen (NL) Nijmegen 24 310.Univ Med Ctr Leiden (NL) Leiden 13 22.J Bosch 'S Hertogenb (NL) 's-Hertogenbosch 6 Grand Total 75 ST-006-AF-01 Page 1 of 4 Template version 2 Short Study Report for Health Authorities EORTC Name of Individual study Table Referring to Part of the Dossier (For National Authority Use Sponsor/Company: Only) EORTC Name of the Volume: finished product Name of Active Page Ingredients: Clofarabine Cytarabine Idarubicin Publication Willemze R, Suciu S, Muus P, Halkes CJ, Meloni G, Meert L, Karrasch M, Rapion J, (reference) Vignetti M, Amadori S, de Witte T, Marie JP.Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • How to Manage Acute Promyelocytic Leukemia
    Leukemia (2012) 26, 1743 -- 1751 & 2012 Macmillan Publishers Limited All rights reserved 0887-6924/12 www.nature.com/leu HOW TO MANAGEy How to manage acute promyelocytic leukemia J-Q Mi, J-M Li, Z-X Shen, S-J Chen and Z Chen Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML). The prognosis of APL is changing, from the worst among AML as it used to be, to currently the best. The application of all-trans-retinoic acid (ATRA) to the induction therapy of APL decreases the mortality of newly diagnosed patients, thereby significantly improving the response rate. Therefore, ATRA combined with anthracycline-based chemotherapy has been widely accepted and used as a classic treatment. It has been demonstrated that high doses of cytarabine have a good effect on the prevention of relapse for high-risk patients. However, as the indications of arsenic trioxide (ATO) for APL are being extended from the original relapse treatment to the first-line treatment of de novo APL, we find that the regimen of ATRA, combined with ATO, seems to be a new treatment option because of their targeting mechanisms, milder toxicities and improvements of long-term outcomes; this combination may become a potentially curable treatment modality for APL. We discuss the therapeutic strategies for APL, particularly the novel approaches to newly diagnosed patients and the handling of side effects of treatment and relapse treatment, so as to ensure each newly diagnosed patient of APL the most timely and best treatment. Leukemia (2012) 26, 1743--1751; doi:10.1038/leu.2012.57 Keywords: acute promyelocytic leukemia (APL); all-trans-retinoic acid (ATRA); arsenic trioxide (ATO) INTRODUCTION In this review, we introduce the therapeutic strategies of APL, Acute promyelocytic leukemia (APL) is a distinct subtype of acute including the treatment of newly diagnosed and relapsed myeloid leukemia (AML) characterized by its abnormal promye- patients, as well as the ways to deal with the side effects.
    [Show full text]
  • HYDREA Product Monograph
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr HYDREA® Hydroxyurea Capsules, 500 mg USP Antineoplastic Agent Bristol-Myers Squibb Canada Date of Initial Authorization: Montreal, Canada MAR 23, 1979 Date of Revision: AUGUST 10, 2021 Submission Control Number: 250623 HYDREA® (hydroxyurea) Page 1 of 26 RECENT MAJOR LABEL CHANGES 1 Indications 02/2020 7 Warnings and Precautions, Hematologic 08/2021 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ........................................................................................... 22 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................. 4 4 DOSAGE AND ADMINISTRATION .................................................................................. 4 4.1 Dosing Considerations ............................................................................................
    [Show full text]